News

Shane Ray Appointed as President and Chief Executive Officer of Hemanext

Hemanext Inc., a leading innovator in blood processing, storage and transfusion technology, is pleased to announce that the Board has appointed Shane Ray to take on the role of President and Chief Executive Officer of Hemanext from Andy Dunham. Shane will also retain his role as the Chief Commercial Officer to lead the global commercial strategy and sales team while Andy will remain on the Executive Leadership Team as Hemanext’s Chief Scientific Officer.

To his immense credit, Andy initiated the conversation with the Board that now was the right time to transition Hemanext’s CEO role to a person with deeper commercial knowledge and experience. Shane has over 20 years in global leadership within the med-tech industry, arriving at Hemanext from curasan Inc, where he was the North American President and Global Chief Marketing Officer.

In the short time Shane has been with Hemanext, he has demonstrated a keen sense of what needs to be done to be successful and, importantly, possesses the right demeanor and approach to lead the organization forward. By also remaining as Chief Commercial Officer, Shane will remain strongly focused on commercial execution during this pivotal period for Hemanext.

Andy’s commitment is to the Company, and he has an intense desire to help it achieve further success. The Board is pleased that Andy will continue as Chief Scientific Officer of Hemanext. Andy’s more than 25 years of experience in R&D and product development at Baxter Healthcare and Hemanext remains invaluable as Hemanext pursues its development goals.

“As I hand the reins to Shane”, said Andy Dunham, CSO and outgoing CEO of Hemanext, “I’m filled with confidence that this leadership transition marks the start of an exciting new phase for our company. With his vision and drive, I’m certain we’ll see a further acceleration in our commercial momentum and a deepening of our impact in the market.”

“I’m excited to lead Hemanext into its next chapter of commercial growth building on the strong evidence and foundation of Hemanext ONE®. Together with our talented team and partners, we will accelerate our mission of “Preserving What is Vital to Life” by providing meaningful benefits to patients and healthcare systems worldwide,” stated Shane Ray, CEO of Hemanext.

Steve Eckert, Chairman of the Board, said, “The Board of Directors enthusiastically approved this transition and is excited to have two such talented leaders on the Hemanext Team. Hemanext’s management under Andy’s leadership has achieved much to reach the cusp of broad commercial adoption of Hemanext ONE. The acceleration of market access since Shane’s appointment as CCO gives me great confidence that his elevation to become CEO will propel Hemanext forward.”

About Hemanext

Hemanext Inc. is a privately held medical technology company based in Lexington, MA dedicated to improving the quality, safety, efficacy and cost of transfusion therapy. Hemanext’s R&D and commercial development efforts focus on the provision of hypoxically stored red blood cells to significantly improve patient outcomes worldwide.

About HEMANEXT ONE

HEMANEXT ONE is a first in class disposable medical device designed to improve the quality of red blood cells for transfusion. HEMANEXT ONE has been granted marketing authorization for commercial distribution through the De Novo process by the U.S. Food & Drug Administration further exhibiting Hemanext ONE’s innovative status and commercial impact. In Europe, HEMANEXT ONE is CE-marked allowing commercial distribution within the European Economic Area (EEA) and the United Kingdom.

Hemanext Media Contact
Suzanna van Straaten
EMEA Commercial Lead & Head of Global Marketing
Suzanna.vanstraaten@hemanext.com
Mobile: +31 6 12 36 54 61

Previous
Next

By producing higher quality RBCs, the Hemanext ONE system has the potential to enable fewer and more effective transfusions for patients. I am truly excited by the possibility of bringing this improved red blood cell replacement therapy to populations in the U.S. that have been waiting for a transformative technology like this one.

Dr. Philip C. Spinella
Professor, Department of Surgery and Department of Critical Care Medicine at University of Pittsburgh

We value our partnership with Hemanext to enhance blood product quality and availability. Hemanext ONE has the potential to strengthen the resiliency of the blood supply, and this FDA authorization is a significant milestone to that end.

Ralph Vassallo, MD, FACP
Executive Vice President, Chief Medical and Scientific Officer of Vitalant

The Hemanext ONE system offers promise to improve the treatment landscape for patients burdened by transfusions and could be an essential step towards performing fewer and better transfusions. Having long championed Hemanext’s transformative initiatives, I eagerly anticipate witnessing the positive influence, right here in the United States, on the advancement of transfusion therapy quality.

Paul M. Ness, MD
Former Director, Division of Transfusion Medicine at Johns Hopkins University and board member of Hemanext

By deoxygenating red cells and maintaining them in their hypoxic state throughout storage, the resulting red cells experience less oxidative stress and oxidative damage, have improved metabolism, and are also more deformable leading to improved micro vascular profusion and less hemolysis.

Dr. Steven Spitalnik, MD
Co-Director of the Laboratory of Transfusion Biology, Colombia University

The preclinical data by Williams et al. show anaerobically stored RBCs achieve multiple clinically important functional resuscitation goals, with a smaller volume of fluid and the FDA benchmark of 24-hour RBC recovery. I look forward to the clinical trials in bleeding patients.

John Holcomb, MD, FACS
University of Alabama at Birmingham

I have had several patients who have received Hemanext hypoxic blood, and several of the patients have personally said thanks for having been given the opportunity and also that they have felt better after transfusion with hypoxic blood compared to conventional transfusion. One must of course be careful not to attach too much importance to such observations, but I would still like to mention that there has been a remarkable tendency towards this.

Håkon Reikvam, MD, PhD
Professor, Department of Clinical Science, University of Bergen, Norway

CONTACT US  |  TERMS OF USE

PRIVACY & COOKIES POLICY

This website may contain information on products or uses of those products that are not authorized in all countries or regions. Hemanext ONE has been granted marketing authorization for commercial distribution via the De Novo process by the U.S. Food & Drug Administration. In Europe Hemanext ONE is CE marked which allows the medical device to be placed in the market in the EEA. Illustrations are artist’s representations only and should not be considered as engineering drawings or photographs. Hemanext, Hemanext ONE, and the logos are registered trademarks of Hemanext, Inc. © 2026 Hemanext, Inc. All rights reserved.

Contact Us